STOCK TITAN
  1. Home
  2. Sec-filings
  3. VIR
  4. [Form 4] Vir Biotechnology, Inc. Insider Trading Activity

Vir Biotechnology (VIR) director logs preplanned sale of 22,000 shares

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Vir Biotechnology director Vicki L. Sato reported a pre-planned stock sale. On 02/02/2026, she sold 22,000 shares of Vir Biotechnology common stock at a weighted average price of $7.7123 per share under a Rule 10b5-1 trading plan adopted on March 27, 2025.

After this transaction, she beneficially owns 1,144,391 shares directly. A Rule 10b5-1 plan allows insiders to schedule trades in advance, helping separate routine portfolio moves from trading based on nonpublic information.

Positive

  • None.

Negative

  • None.
Insider SATO VICKI L
Role Director
Sold 22,000 shs ($170K)
Type Security Shares Price Value
Sale Common Stock 22,000 $7.7123 $170K
Holdings After Transaction: Common Stock — 1,144,391 shares (Direct)
Footnotes (1)
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.32 to $7.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SATO VICKI L
(Last) (First) (Middle)
C/O VIR BIOTECHNOLOGY, INC.
1800 OWENS STREET, SUITE 900
(Street)
SAN FRANCISCO CA 94158
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/02/2026 S(1) 22,000 D $7.7123(2) 1,144,391 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.32 to $7.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Remarks:
/s/ Vanina de Verneuil, Attorney-In-Fact 02/03/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Vir Biotechnology (VIR) director Vicki L. Sato report?

Director Vicki L. Sato reported selling 22,000 shares of Vir Biotechnology common stock. The sale occurred on 02/02/2026 at a weighted average price of $7.7123 per share and was executed under a pre-established Rule 10b5-1 trading plan.

At what prices did Vicki L. Sato’s VIR shares sell in her latest Form 4?

The reported weighted average sale price was $7.7123 per share. Individual trades occurred in multiple transactions at prices ranging from $7.32 to $7.82, and full breakdown details are available on request from the company, any security holder, or the SEC staff.

How many Vir Biotechnology (VIR) shares does Vicki L. Sato own after this sale?

Following the reported transaction, Vicki L. Sato beneficially owns 1,144,391 shares of Vir Biotechnology common stock directly. This figure reflects her holdings after selling 22,000 shares in the 02/02/2026 transaction disclosed in the Form 4 filing.

Was Vicki L. Sato’s February 2026 VIR stock sale under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected under a Rule 10b5-1 trading plan adopted by Vicki L. Sato on March 27, 2025. Such plans allow insiders to schedule trades in advance, helping separate them from decisions based on nonpublic information.

What does the weighted average price mean in Vicki L. Sato’s VIR stock sale?

The weighted average price of $7.7123 represents the average across multiple sale transactions. Individual trades took place between $7.32 and $7.82 per share, and the reporting person offers to provide exact share counts at each price level upon request.